Catálogo de publicaciones - revistas

<jats:title>Prions enter another domain of life</jats:title> <jats:p> Prions are self-propagating protein aggregates, discovered in connection with the fatal transmissible spongiform encephalopathies in mammals. Prions have also been identified in fungi, where they act as protein-based elements of inheritance. Although prions have been uncovered in evolutionarily diverse eukaryotic species, it is not known whether prions exist in bacteria. Yuan and Hochschild report the identification of a bacterial protein—the transcription termination factor Rho from <jats:italic>Clostridium botulinum</jats:italic> —that exhibits the defining hallmarks of a prion-forming protein. </jats:p> <jats:p> <jats:italic>Science</jats:italic> , this issue p. <jats:related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" issue="6321" page="198" related-article-type="in-this-issue" vol="355" xlink:href="10.1126/science.aai7776">198</jats:related-article> </jats:p>

<jats:title>Designing proteins with cavities</jats:title> <jats:p> In de novo protein design, creating custom-tailored binding sites is a particular challenge because these sites often involve nonideal backbone structures. For example, curved b sheets are a common ligand binding motif. Marcos <jats:italic>et al.</jats:italic> investigated the principles that drive β-sheet curvature by studying the geometry of β sheets in natural proteins and folding simulations. In a step toward custom design of enzyme catalysts, they used these principles to control β-sheet geometry and design proteins with differently shaped cavities. </jats:p> <jats:p> <jats:italic>Science</jats:italic> , this issue p. <jats:related-article xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" issue="6321" page="201" related-article-type="in-this-issue" vol="355" xlink:href="10.1126/science.aah7389">201</jats:related-article> </jats:p>

<jats:p> Applications of the genome editing system CRISPR are appearing at a furious pace, and gathering momentum toward therapeutic use in human cells. Indeed, Chinese scientists recently began a human clinical trial using CRISPR-edited cells to fight lung cancer, and U.S. clinical trials are slated to begin in 2017. But leading up to this exciting milestone, researchers performed some editing on the CRISPR system itself. Here's a look at some recent CRISPR upgrades that are helping to move it closer toward use in clinics. <jats:list list-type="bullet"> <jats:list-item> <jats:p> <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.sciencemag.org/custom-publishing/technology-features/editing-editor-genome-editing-gets-makeover-crispr-20">Read the Feature (Full-Text HTML)</jats:ext-link> </jats:p> </jats:list-item> <jats:list-item> <jats:p> <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.sciencemag.org/sites/default/files/custom-publishing/documents/13JanGenomics.pdf">Read the Feature (PDF)</jats:ext-link> </jats:p> </jats:list-item> <jats:list-item> <jats:p> <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.sciencemag.org/sites/default/files/custom-publishing/douments/13JanNewProducts.pdf">Read New Products (PDF)</jats:ext-link> </jats:p> </jats:list-item> </jats:list> </jats:p>

<jats:p>A weekly roundup of information on newly offered instrumentation, apparatus, and laboratory materials of potential interest to researchers.</jats:p>

<jats:p> In addition to being the first line of defense against pathogenic attack, the immune system seeks out aberrant cells within the body that may become cancerous. In response, precancerous and cancerous cells may exploit immune checkpoint pathways to evade immune detection and destruction. In order to block these tumorigenic cells, novel therapeutics that modulate immune checkpoint signaling have been developed, with some already available and others in clinical trials. Further development of effective therapeutics for use in personalized medicine requires the identification and characterization of a diverse range of immune checkpoint biomarkers. This webinar will explore recent progress and future directions in translational and clinical efforts centered on checkpoint modulators and combination therapies matched to the molecular profile of individual tumors and the genetic background of patients. <jats:list list-type="bullet"> <jats:list-item> <jats:p> <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://webinar.sciencemag.org/webinar/archive/deciphering-cancer-modulating-immunoregulatory-pathways-treat-tumors">View the Webinar</jats:ext-link> </jats:p> </jats:list-item> </jats:list> </jats:p>